| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H48OSe |
| Molecular Weight | 475.6026 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[75Se]C[C@@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCC(C)C)[C@@]3(C)CC[C@@H]2C4=C1C[C@@H](O)CC4
InChI
InChIKey=AEVGUKVBCBHBNF-MJMUOCKJSA-N
InChI=1S/C28H48OSe/c1-18(2)7-6-8-19(3)26-11-12-27-25-15-20(17-30-5)24-16-21(29)9-10-22(24)23(25)13-14-28(26,27)4/h18-21,23,25-27,29H,6-17H2,1-5H3/t19-,20+,21+,23-,25-,26-,27+,28-/m1/s1/i30-4
Se-75 norcholesterol is radiopharmaceutical derivative of cholesterol, a natural precursor in the synthesis of adrenocortical steroid hormones. Se-75 is a radioactive isotope of selenium, it has half-life period of 120 days, and emits gamma-rays upon decay. Se-75 norcholesterol was used under tradename Scintadren to diagnose a wide range of adrenal pathologies, including Cushing syndrome, Cushing's disease, carcinoma, adrenal insufficiency, and phaeochromocytoma. The drug was withdrawn in the early 2000s in favor of I-131 norcholesterol.
Approval Year
ACTIVE MOIETY
